Views & Analysis The shadow of Brexit on speed of access No-one can miss the ongoing saga that is the UK’s exit from the European Union (EU).
Views & Analysis Access to new medicines in Scotland: a perennial issue Access to new medicines in Scotland – just as it would seem is the case everywhere – is always on the agenda.
News BioMarin snaps up Alesta's lead asset for $275M BioMarin will acquire Alesta's experimental therapy for rare bone disease hypophosphatasia for up to $490 million.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
